Anti-obesity effect of Stellaria media methanolic extract in the murine model of cafeteria diet induced obesity

Chidrawar, Vijay R.; Patel, Krishnakant N.; Bothra, Sunil B.; Shiromwar, Shruti S.; Koli, Akshay R.; Kalyankar, Gajanan G.
May 2012
International Journal of Nutrition, Pharmacology, Neurological D;May2012, Vol. 2 Issue 2, p121
Academic Journal
Context: The whole plant of Stellaria media Linn (family Caryophyllaceae) is used by the local people of Dibrugarh district of Assam state, India, as a dietary supplement for the treatment of overweight and is also mentioned in the traditional system of Indian medicine as a remedy for obesity. Moreover phytoconstituents like flavonoid, saponin, and sitosterol have already been reported for their anti-obesity activity, and the extract of S. media also contains the same constituents in its extracts. With this background, this study was carried out. Objective: The anti-obesity activity of the alcoholic and methanolic extracts of Stellaria media was evaluated against the cafeteria diet-induced obesity model in female Wistar rats. Materials and Methods: Obesity was induced by feeding a cafeteria diet for 48 days to female Wistar rats, although one group was kept on a normal chow diet to evaluate the effect of Stellaria media on body weight changes, exploratory behavior, theromogenesis, lipid metabolism, effect on White Adipose Tissue (WAT), and histology of the fat pad. Results: Among these two extracts, the methanolic extract of Stellaria media (MESM) has shown a strong anti-obesity effect compared to the alcoholic extract of Stellaria media (AESM); may be because of its multiple mechanisms. The LD50 value was found to be more than 5000 mg/kg. Discussion and Conclusion: These findings suggest that the anti-obesity activity produced by MESM may be because of the flavonoid and saponin contents, which have thermogenic and appetite-suppressant properties or it may be due to the ß-sitosterol content. With this study we conclude that MESM is beneficial for the suppression of obesity and its associated complications.


Related Articles

  • Options for treating obesity. Campbell, Ian // GP: General Practitioner;4/26/2002, p70 

    Focuses on the options for general practitioners in treating obesity. Effectiveness of anti-obesity drugs; Requirements for drug administration; Importance of setting realistic targets.

  • Long-Term Results of Drug Treatment for Obesity. SLAWSON, DAVID // American Family Physician;3/1/2014, Vol. 89 Issue 5, p389 

    The article presents answers to a question on whether weight loss medications are effective as long-term treatment for obesity.

  • 5 that work. Nachatelo, Melissa // Natural Health;May/Jun2001, Vol. 31 Issue 4, p70 

    Presents information about different natural diet supplements used in the management of obesity. Green tea; Ephedra; Chromium.

  • New experimental drug helps obese patients lose weight.  // New York Amsterdam News;02/25/99, Vol. 90 Issue 9, p14 

    Highlights the results of a study conducted at Baylor College of Medicine in Houston, Texas indicating the potency of orlistat to promote weight loss among obese patients. Need for the combination of moderate-calorie diet; Mechanism of the drug's action; Adverse reactions.

  • Focus On Orlistat: A Nonsystemic Inhibitor Of Gastrointestinal Lipase For Weight Reduction In The Management Of Obesity. Chow, Moses S.S.; Reddy, Prabashni // Formulary;Oct98, Vol. 33 Issue 10, p943 

    Discusses orlistat, a nonsystemic inhibitor of gastrointestinal lipase for weight reduction in the management of obesity. Chemistry and pharmacology; Pharmacokinetics; Clinical trials; Guidelines for obesity therapy; Adverse effects; Drug interaction; Dosage. INSET: Formulary Considerations.

  • Safety profile of orlistat: results of a prescription-event monitoring study. Acharya, N. V.; Wilton, L. V.; Shakir, S. A. W. // International Journal of Obesity;Nov2006, Vol. 30 Issue 11, p1645 

    Introduction:Orlistat, the first of a new class of drugs for the treatment of obesity, was launched in the UK in December 1998. The prescribing information recommends that treatment with orlistat should be discontinued after 12 weeks if the patient has not achieved a specified loss of...

  • Profit in Loss. Wellner, Alison Stein // American Demographics;Jul2000, Vol. 22 Issue 7, p46 

    Discusses the development of the XeniCare program offered to patients using the Roche Laboratories' Xenical prescription obesity drug.

  • Pharmacologic Treatment of Obesity. Halpern, Alfredo; Heymsfield, Steven B.; Van Gaal, Luc // Journal of Obesity;2011, Vol. 2011, Special section p1 

    The article provides information on the CB1 receptor antagonist Rimonabant which was introduced in the European mass market showing weight loss benefits. Following the emergence of significant side effects, including severe mood disorders, the drug was withdrawn from the market. Several lessons...

  • Press coverage and sales of Xenical in Sweden, 1998—2000. Brounéus, Fredrik; Dahlin, Anna; Beermann, Björn // European Journal of Clinical Pharmacology;Jun2005, Vol. 61 Issue 4, p285 

    Objective: The anti-obesity drug Xenical (orlistat, Roche) was launched on the Swedish market in February 1999. The sales peaked in May 1999 and then declined. The purpose of this study was to investigate the press coverage of Xenical during the period 1998–2000 and, if possible, relate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics